
## **Product Data Sheet**

## **PerCP anti-mouse CD69**

| Catalog # / Size:  | 1122600 / 100 μg   |
|--------------------|--|
| Clone:             | H1.2F3   |
| Isotype:           | Hamster IgG  |
| Immunogen:         | Mouse dendritic epidermal T cell line<br>Y245  |
| <b>Reactivity:</b> | Mouse  |
| Preparation:       | The antibody was purified by affinity  |
|                    | chromatography, and conjugated with<br>PerCP under optimal conditions. The<br>solution is free of unconjugated PerCP<br>and unconjugated antibody. |
| Formulation:       | PerCP under optimal conditions. The solution is free of unconjugated PerCP   |



PMA + ionomycin-stimulated (6 hrs) C57BL/6 splenocytes stained with H1.2F3 PerCP

## **Applications:**

| Applications:              | Flow Cytometry   |
|----------------------------|--|
| Recommended<br>Usage:      | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is $\leq 0.25$ microg per $10^6$ cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.   |
|                            | * PerCP has a maximum absorption of 482 nm and a maximum emission of 675 nm.   |
| Application<br>Notes:      | The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: <i>in vitro</i> T cell and NK cell activation <sup>1-3</sup> , immunohistochemistry <sup>4,5</sup> , and immunoprecipitation1.  |
|                            | This antibody has been characterized in the literature as containing a $\lambda$ ( $\lambda$ ) light chain.  |
| Application<br>References: | <ol> <li>Yokoyama WM, <i>et al.</i> 1988. <i>J. Immunol.</i> 141:369. (IP)</li> <li>Sobel ES, <i>et al.</i> 1993. <i>J. Immunol.</i> 150:673.</li> <li>Karlhofer FM, <i>et al.</i> 1991. <i>J. Immunol.</i> 146:3662.</li> <li>Zhou X, <i>et al.</i> 2005. <i>J. Biol. Chem.</i> 280:31240. (IHC)</li> <li>Podd BS, <i>et al.</i> 2006. <i>J. Immunol.</i> 176:6532. (IHC)</li> <li>Lawson BR, <i>et al.</i> 2007. <i>J. Immunol.</i> 178:5366.</li> <li>Lee JW, <i>et al.</i> 2008. <i>Nature Immunol.</i> 8:181.</li> <li>Epardaud M, <i>et al.</i> 2008. <i>T6</i>:3717. <u>PubMed</u></li> <li>Kenna TJ, <i>et al.</i> 2008. <i>Blood</i> 111:2091. <u>PubMed</u></li> <li>Ishikawa C, <i>et al.</i> 2013. <i>Biochim Biophys Acta.</i> 167:99. <u>PubMed</u></li> </ol> |
|                            |  |

**Description:** CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfidelinked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Antigen1. Barclay AN, *et al.* 1997. The Leukocyte Antigen FactsBook Academic Press.References:2. Testi R, *et al.* 1994. *Immunol. Today* 15:479.3. Moretta A, *et al.* 1991. *J. Exp. Med.* 174:1393.

4. Yokoyama WM,